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IDN 5390 is a novel C-seco taxane analogue selected for preclinical development on the basis of its antimotility activity on
endothelial cells, antitumour efficacy in a large panel of human tumour xenografts and high tolerability in mouse. On the basis of oral
availability, IDN 5390 is suitable for protracted administration schedules. Such a treatment schedule has been reported as the most
appropriate to exploit the antiangiogenic effects of cytotoxic drugs. An ability to downregulate angiogenesis-related growth factors in
tumour cells has been described for IDN 5390. The aim of the study was to investigate the antitumour and antiangiogenic potential of
oral IDN 5390 on a human ovarian carcinoma xenograft, the INT.ACP/PTX, resistant to paclitaxel (PTX). Such tumour line was
derived in vivo from a cisplatin-resistant tumour line, the A2780/DDP, which is sensitive to PTX. Compared to the parental cells,
INT.ACP/PTX cells exhibited a high level of Pgp expression, resulting in a reduced in vitro sensitivity to both PTX and IDN 5390. The
INT.ACP/PTX tumour xenograft was still resistant to PTX, but responsive to IDN 5390, when delivered per os, by a daily prolonged
schedule. A direct effect on tumour cells, allowed by the high tolerability of the compound in mouse, cannot be excluded in vivo.
Immunohistochemical analysis indicated a significant reduction of microvessel density in IDN 5390-treated tumours, lasting till 7 days
after the last drug administration. Thus, a prolonged inhibitory effect on tumour angiogenesis is consistent with the persistent growth
control of INT.ACP/PTX tumour achieved by IDN 5390. On the contrary, the low tolerability and the limited oral availability of
conventional taxanes do not allow an easy feasibility of such treatment regimen. Thus, the tolerability profile of IDN 5390 in
preclinical systems and its efficacy in PTX-resistant tumours support the therapeutic interest for its clinical development, with
particular attention to oral daily prolonged schedules.
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Taxanes are effective antitumour agents characterised by a unique
mechanism of action, that is, microtubule polymerisation resulting
in cell death following arrest of cell cycle in M phase and formation
of aberrant mitoses (Horwitz et al, 1993; Jordan et al, 1993). In
addition to the cytotoxic effects on tumour cells, effects on
angiogenesis have been reported for paclitaxel (PTX) and
docetaxel, the two taxanes currently used in clinics (Verweij et al,
1994; Rowinsky, 1997). These effects have been related to the
ability of inhibiting endothelial cell motility (Belotti et al, 1996;
Sweeney et al, 2001) and downregulating angiogenesis-related
growth factors (Cassinelli et al, 2002). The novel C-seco taxane
IDN 5390, which is currently under study in preclinical systems,
was originally selected for its potent antimotility activity and low
cytotoxicity in endothelial cells (Taraboletti et al, 2002). In vivo
studies in human tumour xenografts have indicated a unique
profile of tolerability and antitumour activity for IDN 5390 when
administered by a daily schedule for a prolonged time (Pratesi et al,
2003).
In recent years, many preclinical studies have indicated the
possibility of using cytotoxic drugs as antiangiogenic agents for the
antitumour therapy. Chronic and frequent treatment schedules
have been reported as the most appropriate to exploit the
antiangiogenic effect of cytotoxic drugs, compared to the high-
dose/intermittent-schedule mainly targeting tumour cells (Hana-
han et al, 2000; Miller et al, 2001). Conventional antitumour drugs
delivered according to the so-called ‘metronomic chemotherapy’
were effective even against drug-resistant tumours (Browder et al,
2000; Fidler and Ellis, 2000). When administered according to a
frequent and prolonged schedule, IDN 5390 is active against all
human tumour xenografts investigated, including the PTX-
resistant ones (Pratesi et al, 2003).
The aim of the study was to further investigate the mechanisms
responsible for the antitumour activity of IDN 5390 in PTX-
resistant human tumour xenografts and, in particular, in the
ovarian carcinoma INT.ACP/PTX. Such tumour line was derived in
vivo by one single s.c. growing A2780/DDP tumour xenograft
(cisplatin-resistant) after treatment with PTX. The mechanisms of
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sresistance of these tumour cells and the in vivo antiangiogenic
effect of the drug were investigated. The results are consistent with
a contribution of antiangiogenic effects in the antitumour efficacy
of the taxane analogue.
MATERIALS AND METHODS
Drugs, tumour and cells
IDN 5390, (13-(N-Boc-b-isobutylisoserinyl)-10b-dehydro-C-seco-
10-deacetylbaccatin III) and PTX, used as reference drug, were
provided by Indena S. p.a. (Milan, Italy) (Figure 1). For in vitro
studies, drugs were dissolved in dimethylsulphoxide (DMSO) at
2mgml
 1 and diluted in culture medium (DMSO final concentra-
tion 0.25%). For in vivo studies, PTX was dissolved by adding
absolute ethanol and Cremophor ELP (both 5% of the final
volume) (Polizzi et al, 1999), whereas IDN 5390, dissolved in
Polysorbate 80, was diluted just before use by adding 0.9% NaCl to
the final concentration of 10% vv
 1 (Pratesi et al, 2003).
The study was performed on the A2780 human ovarian
carcinoma cell line and two variants, that is, the A2780/DDP cell
subline, selected in vitro for resistance to cisplatin (Beherens et al,
1987), and the INT.ACP/PTX cell subline. The latter variant was
derived from a single A2780/DDP tumour xenograft which,
unexpectedly, was not responding to PTX treatment in vivo.
Indeed, the A2780/DDP tumour line is highly sensitive to PTX
treatment (Polizzi et al, 1999). The line was maintained either by
s.c. passages of tumour fragments (tumour line) or as cell culture
(cell line). A2780/DX, selected in vitro for acquired resistance to
doxorubicin, was used as positive control for the Pgp expression
analysis.
All cell lines were maintained in RPMI 1640 (Bio-Whittaker
Verviers, Belgium) supplemented with 10% foetal calf serum (Life
Technologies, Gaithersburg, MD, USA) in 5% CO2 atmosphere.
In vitro studies
Tumour cell sensitivity to IDN 5390 and PTX was evaluated by cell
growth inhibition assay. Cells were seeded in six-well plates in
duplicate and after 24h exposed to the solvent or to the drugs at
different concentrations. After 72h, cells were trypsinised and
counted by a Coulter Counter (Coulter Electronics, Luton, UK).
The concentration able to inhibit cell proliferation by 50% (IC50)
was derived by dose/effect plots. Resistant Index (RI) was assessed
as the ratio between the drug IC50 in each cell subline and in the
parental A2780 cell line.
For the MDR phenotype characterisation, the Pgp expression
was determined by immunofluorescence (Gottesman and Pastan,
1993). Cells (10
6) were trypsinised and washed in PBA (phosphate-
buffered saline (PBS) and 1% bovine serum albumin (BSA)). Cells
were then incubated in 100ml of PBA containing 10ml of gp170-
FITC antibody (YLEM, Rome, Italy). After washing in PBS,
expression of the protein was assessed as fluorescence intensity
using a FACScan (Becton Dickinson, Mountain View, CA, USA).
Bcl-2 expression was examined in whole-cell extracts prepared
as previously reported in Pratesi et al (2003). Briefly, equal
amounts of proteins were separated by SDS–PAGE and transferred
onto nitrocellulose sheets. Then filters were incubated with mouse
monoclonal anti-Bcl-2 antibody (Santa Cruz Biotechnology, CA,
USA) or with rabbit polyclonal antiactin (Sigma, St Louis, MO,
USA). Immunocomplexes were visualised by the Pierce Super
Signal System (Pierce, Rockford, IL, USA).
In vivo studies
All the experiments were carried out using adult (8–10 weeks old)
female athymic CD-1 nude mice (Charles River, Calco, Italy). Mice
were maintained in laminar flow rooms at constant temperature
and humidity, with free access to sterilised food and water.
Experimental protocols were approved by the Ethic Committee for
Animal Experimentation of our Institute (Istituto Nazionale per lo
Studio e la Cura dei Tumori, Milan, Italy), according to the United
Kingdom Coordinating Committee on Cancer Research Guidelines
(Workman et al, 1998).
The INT.ACP/PTX tumour was maintained in line by subse-
quent fragment implants, as previously described (Pratesi et al,
1989). At each passage mice were treated with PTX (i.v.,
36mgkg
 1, 7 days after tumour inoculum), and in such conditions
tumour weight inhibition (TWI) induced by the optimal PTX
regimen was lower than 50 vs a 94% inhibition in the A2780/DDP
tumour line (Polizzi et al, 1999).
Drug solutions of 3.6 and 9mgml
 1 were prepared, as described
above, for PTX and IDN 5390, respectively, corresponding to 36
and 90mgkg
 1 for an administration volume of 10mlkg
 1 of body
weight. Larger volumes were injected for higher doses.
For experimental purposes, tumour fragments were s.c.
implanted in the right flank of mice. Tumour growth was followed
by biweekly measurements of tumour diameters with a Vernier
caliper. Tumour weight (TW) was calculated according to the
formula: TW (mg)¼tumour volume (mm
3)¼d
2 D/2, where d
and D are the shortest and the longest diameter, respectively. Mice
bearing tumours of 250–300mg were treated with IDN 5390 and
PTX, according to different treatment routes (i.v., s.c. or p.o.) and
schedules (daily, i.e. qd 8, or intermittent, i.e. q4d 3). The first
and the last day of treatment were the same for the two schedules.
At 1 and 7 days after treatment end, three mice/group were killed
by cervical dislocation. Tumours were excised, weighed, fixed in
zinc fixative and stained with standard haematoxylin—eosin in
order to study the overall tissue morphology. Angiogenesis was
assessed by immunohistochemistry (IHC), staining blood vessels
with a rat anti-mouse CD31/PECAM-1 monoclonal antibody
(kindly supplied by Dr A Vecchi, Mario Negri Institute, Milan,
Italy), as previously described (Cassinelli et al, 2002). Microvessel
density (MVD) was determined using a WebSlide Browser
software. Briefly, microvessels were quantified within six
random fields (0.159mm
2 fields,  200 magnification) selected
for high vascularisation (hot spot areas). Microvessel density was
expressed as mean number7s.d. Percentage MV inhibition
(MVI%) in drug-treated vs control mice was calculated as
MVI%¼100–(mean MVD in treated/mean MVD in control
tumours 100). Neither vessel lumen nor red blood cells were
used to define a microvessel. Scoring of histological tumour
sections was performed by two independent observers, without
knowledge of the experimental group, with an interobserver
reproducibility 495%.
Drug efficacy was assessed, at the last day of treatment, as
percentage TW inhibition (TWI%) expressed as TWI%¼100–
(mean TW treated/mean TW control 100).
For statistical analysis, TW and MV number were compared in
treated vs control mice by the unpaired Student’s t-test (two-
tailed).
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IDN 5390 Paclitaxel
Figure 1 Chemical structures of paclitaxel and IDN 5390.
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sRESULTS
Chemosensitivity and drug resistance
Pgp overexpression is a frequent mechanism of the cellular
resistance to hydrophobic drugs, including PTX (Horwitz et al,
1993; Zunino et al, 1999). Thus, the Pgp expression levels were
investigated by FACS analysis in the parental A2780 and in its
variant cell lines (Figure 2). Pgp was expressed at low level in
A2780 and A2780/DDP cells (mean fluorescence intensity being 8.5
and 7.9, respectively), whereas an increased expression was found
in INT.ACP/PTX cells (mean fluorescence intensity, 25). A2780/DX
cells were used as a positive control because of their MDR
phenotype (mean fluorescence intensity, 140). Since Pgp expres-
sion can be modulated by treatment with drugs that are substrates
for the transport system (Gottesman and Pastan, 1993), the protein
level was examined after 72 h-treatment with PTX or IDN 5390. As
shown in Figure 3 an increased Pgp level was found in A2780/DDP
cells after exposure to taxanes, whereas no significant modulation
was observed in A2780 (not shown) and INT.ACP/PTX cells.
The antiproliferative effects of PTX and IDN 5390 after 72h of
treatment indicated an inverse correlation between Pgp expression
and cell sensitivity to the taxanes (Table 1). Thus, A2780/DX and
INT.ACP/PTX cells exhibited a reduced sensitivity to both taxanes.
However, a lower Resistance Index (RI) was observed for IDN 5390
than for PTX. Co-treatment of INT.ACP/PTX cells with each taxane
and the pump-antagonist verapamil (10mM) resulted in a complete
reversal of resistance, with IC50 values similar to those in the
A2780/DDP cell line, that is, 17.571.2 and 5774n M for PTX and
IDN 5390, respectively (not shown).
A differential expression of Bcl-2 protein was detected by
Western Blot analysis in the cell lines. A2780/DDP cell lines
showed increased basal levels of this protein compared to the
parental A2780 cell line. No Bcl-2 protein was detectable in
INT.ACP/PTX cells by this technique (Figure 4).
In vivo studies
We have already reported that the INT.ACP/PTX tumour xenograft
is resistant to PTX (less than 50% TWI), but highly sensitive (87%
TWI) to IDN 5390, 120mgkg
 1, delivered twice a day for 15 days
(Pratesi et al, 2003). In the present study, the same dose of IDN
5390 was delivered only once a day for eight treatments, and a
lower antitumour effect (60% TWI) was achieved (Table 2).
Anyway, IDN 5390 resulted much more effective than PTX
delivered in similar conditions (Po0.005), or at its best regimen
(Po0.05).
A prolonged treatment schedule, which resulted to be the
optimal one for the antitumour efficacy of IDN 5390, has been
reported as the most suitable for exploiting the antiangiogenic
effect of cytotoxic drugs. Thus, the effect on angiogenesis of the
Figure 2 Pgp expression in the A2780 and its variant cell lines. A2780/
DX cells were used as positive control. Protein expression was assessed as
fluorescence intensity in logarithmically growing cells stained with gp170-
FITC antibody. One experiment representative of two for each cell line is
reported.
Figure 3 Pgp expression in A2780/DDP and INT.ACP/PTX cell lines
treated with PTX or IDN 5390. Protein expression was assessed as
fluorescence intensity in cells treated with the IC80 of each drug for 72h
and stained with gp170-FITC antibody. One experiment representative of
two for each cell line is reported.
Table 1 Antiproliferative activity of IDN 5390 and PTX on different
human ovarian tumour cell lines
PTX IDN 5390
IC50
a (nM)R I
b IC50
a (nM)R I
b
A2780 9.5712 9 70.5
A2780/DDP 13.871.7 1.5 40.477 1.4
INT.ACP/PTX 140723 15 203735.5 7
A2780/DX 366730 38.6 424744.4 14.5
aIC50: drug concentration required to inhibit 50% of cell growth compared to
untreated cells (72h of drug exposure). Mean7s.d. of at least three independent
experiments are reported.
bResistance Index (RI), calculated as the ratio between the
IC50 of the cell sublines and the IC50 of the parental A2780 cell line.
Figure 4 Expression of Bcl-2 protein in A2780 and its variant cell lines.
Equal amounts of proteins were separated by SDS–PAGE and analysed by
immunoblotting. Control for protein loading by actin is shown.
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snovel taxane was assessed in INT.ACP/PTX tumour xenografts
(Table 2 and Figure 5). The MVD analysis performed one day after
the last drug treatment (þ1) clearly showed that both drugs,
delivered by the daily schedule, significantly decreased MVD vs
control tumours (55 and 50% MVI, respectively; Po0.0001 for
both). Paclitaxel was administered daily by the s.c. route, due to its
very poor oral bioavailability (Sparreboom et al, 1997; Polizzi et al,
2000). After 1 week (þ7), a significant inhibitory effects on MVD
was still present only in the IDN 5390-treated tumours (Po0.05).
Paclitaxel administered i.v. at its best regimen for antitumour
activity (high-dose/intermittent schedule) had limited effect on
tumour angiogenesis.
DISCUSSION
Resistance to taxanes involves several mechanisms including mdr
gene amplification or overexpression and alterations in drug–
target interactions (Horwitz et al, 1993). Indeed, mdr-1 gene
expression has been associated with the development of PTX
resistance in patients with ovarian cancer (Kamazawa et al, 2002).
In contrast, b-tubulin mutations have been reported to be rare in
newly diagnosed and in recurrent PTX-resistant human ovarian
cancer patients (Lamendola et al, 2003). The tumour line
investigated in the study, INT-ACP/PTX, was originated following
in vivo treatment with PTX. Such a model, as far as we know, is the
first experimental system where tumour resistance to PTX was
acquired in vivo, using therapeutic doses of the drug. Our results
indicate that in the INT.ACP/PTX tumour cells the resistance to
PTX was mediated by expression of Pgp, because tumour cells
displayed an increased expression of Pgp protein compared to the
parental cell line A2780/DDP. The high susceptibility of A2780/
DDP cells to acquire an MDR phenotype was supported by the
increased expression of Pgp observed after treatment with taxanes
in such cells.
Recently, Bcl-2 downregulation has been reported as another
resistance mechanism to PTX (Ferlini et al, 2003). The Bcl-2
protein is downregulated in the resistant INT.ACP/PTX cells
compared to the A2780/DDP cells. However, the relevance of this
finding in the resistant phenotype remains to be defined. Indeed,
the almost complete reversal of resistance to PTX by verapamil
supports a typical MDR-mediated resistance.
In the present study IDN 5390, 120mgkg
 1, administered once a
day for 8 days induced a marginal tumour response (60% TWI),
whereas a superior antitumour effect (87% TWI) was achieved by
the same dose twice a day for 2 weeks (Pratesi et al, 2003). Indeed,
the very low toxicity of the compound allows very frequent drug
administration and very prolonged period of treatment. Indeed,
total doses up to 4.5gkg
 1, that is, 20-fold higher than those of PTX,
were well tolerated (Pratesi et al, 2003). Thus, in spite of the
recognition by transport systems detected in cell systems (Distefano
et al, 1998; our results), a contribution of cytotoxic effect in
antitumour activity of IDN 5390 could be expected. Indeed, the
previously reported plasma levels of IDN 5390 in mouse (Cmax,
25mgml
 1) after oral administration of a single dose (120mgkg
 1)
are high enough to support our interpretation (Pratesi et al, 2003).
Tumour growth inhibition by IDN 5390 was associated with a
strong reduction of tumour MVD, which was more evident 1 day
after treatment end (55% MVI) and still present 1 week after (26%
MVI). Such finding was in keeping with other preclinical in vivo
studies on inhibition of tumour angiogenesis by various cytotoxic
drugs delivered by the so-called ‘metronomic chemotherapy’, that
is, frequent and prolonged administration schedule in contrast to
the conventional high-dose/intermittent-schedule regimen (Hana-
han et al, 2000; Schirner, 2000; Miller et al, 2001). Indeed, the
conventional regimen of PTX (i.v., high-dose/intermittent-treat-
ment) compared to the daily schedule, achieved a superior level of
antitumour activity (31 vs 0% TWI), but a lower effect on MVD.
Inhibition of angiogenesis in the INT.ACP/PTX tumour xenograft
was achieved also by PTX delivered by the daily s.c. treatment. The
reduction on MVD was similar to that achieved by the analogue,
but PTX-induced effect was less persistent. No antitumour efficacy
was achieved by PTX delivered by these conditions. In spite of a
similar ability to inhibit tumour angiogenesis, the limited exposure
of the tumour cells to PTX, due to the low drug tolerability in vivo,
may account for the lack of efficacy of PTX. In addition, the higher
level of resistance (RI 15 vs 7 for PTX and IDN 5390, respectively)
may be a further drawback of PTX. Moreover, considering the very
poor oral bioavailability of PTX (Sparreboom et al, 1997; Polizzi
Table 2 Antitumour and antiangiogenic effects of IDN 5390 and PTX delivered by different treatment schedules against the INT.ACP/PTX human
ovarian tumour xenograft
Dose (mgkg
 1) Treatment MVI%
b
Drug Route Single Total Schedule Days TWI%
a +1 +7
PTX s.c. 10 80 Daily 8 4–11 0
ww 50** 21
i.v. 54 162 q3-4d 3 4,7,11 31
w 26* 14
IDN 5390 p.o. 120 960 Daily 8 4–11 60 55** 26*
aTumour weight inhibition percentage, evaluated 1 day after the last treatment. TW in controls was mg 4257235 (mean7s.d.).
bTumour Microvessel Inhibition percentage,
assessed 1 and 7 days after the last treatment. Microvessel numbers in control tumors were 1875 and 1272.6 (mean7s.d.) at 1 and 7 days, respectively.
wPo0.05 and
wwPo0.005 vs IDN 5390-treated mice; *Po0.05 and **Po0.0001 vs control tumours, by Student’s t-test.
+7 days +1 day
Controls PTX 
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Figure 5 Microvessel density in INT.ACP/PTX tumour xenograft after
IDN 5390 or PTX treatment. Tumours were implanted s.c. in mice and
treated with: solvent (empty column); IDN 5390 120mgkg
 1, per os,
daily 8 (black column); PTX 10mgkg
 1, s.c., daily 8 (dark grey column);
PTX 54mgkg
 1, i.v., q4d 3 (light grey column). At 1 or 7 days after last
treatment, tumours were surgically removed, and MVD was evaluated by
immunoistochemical analysis (see Materials and Methods). Columns
represent the mean MVD7s.d. *Po0.05, **Po0.0001 vs control tumours,
by Students’ t-test.
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set al, 2000), the s.c. route was used for the daily treatment, and
only 10mgkg
 1 were tolerated, due to the high vesicant activity of
the drug (Pratesi et al, 2003). In contrast, the possibility of
delivering repeated administrations of IDN 5390 allows keeping
tumour angiogenesis under control for long time. The effects of
IDN 5390 on tumour angiogenesis in vivo are consistent with its
ability to inhibit endothelial cell motility (Taraboletti et al, 2002) as
well as to downregulate the expression of angiogenic growth
factors (Pratesi et al, 2003). Downregulation of VEGF and bFGF
expression, already reported in a glioma cell line (Pratesi et al,
2003), was observed even in INT-ACP/PTX cells (not shown). Thus,
the responsiveness of the tumour to IDN 5390 may be the result of
the contribution of both antiangiogenic and cytotoxic effects.
In conclusion, the relevant antitumour activity of the novel
taxane IDN 5390 against a PTX-resistant tumour xenograft is likely
to be the result of multiple actions, favoured by the peculiar
pharmacological properties of the compound. Indeed, the good
tolerability in vivo and the oral bioavailability allow exploiting the
therapeutic potential of high doses of the drug (possibly allowing
direct cytotoxicity) throughout a continuous and prolonged period
of treatment (favouring effect on angiogenesis inhibition).
Although the therapeutic advantages of IDN 5390 over PTX could
be achieved only at relatively high dose levels, the favourable
pharmacological profile makes IDN 5390 a promising candidate
for clinical development.
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